More than 800 million adults have diabetes worldwide – almost twice as many as previous estimates have suggested – and more than half of those aged over 30 who have the condition are not receiving ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers Health on Wednesday launched a tracker for popular weight-loss and diabetes drugs that allows patients to share details about their challenges finding treatments such as Novo Nordisk's ...

After Novo Nordisk and Eli Lilly transformed the market for ... five weekly injections of the highest dose produced a 7.5% ...

Eli Lilly (LLY) and Company announced detailed results from ... Tirzepatide demonstrated sustained average weight loss of 22.9% through the three-year treatment period for the efficacy estimand. These ...

I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

Susan McGowan, a 58-year-old nurse from Scotland, tragically passed away after taking two doses of tirzepatide, a weight-loss ...

In recent years, interest in these medications—initially developed to treat type 2 diabetes—has exploded, primarily because ...